Expanded phase II trial of paclitaxel in metastatic breast cancer

A Southwest Oncology Group study

Charles E. Geyer, Stephanie J. Green, Carol M. Moinpour, Janet O'Sullivan, Donna K. Goodwin, Vikki A. Canfield, Frederick J. Meyers, C. Kent Osborne, Silvana Martino

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background. The study was designed to evaluate the efficacy of paclitaxel in metastatic breast cancer patients. The design was motivated by a report from FDA and NCI staff proposing assessment of pre- and post-treatment symptoms as a means of evaluating treatment effectiveness. Methods. Patients with symptomatic and/or measurable metastatic breast cancer with prior treatment received paclitaxel 210 mg/m2 as a 3 hour infusion every three weeks until toxicity or progression. A unique endpoint was subjective symptomatic response, defined as an improvement in the Symptom Distress Scale score by ≥ 3 points at two successive evaluations before treatment failure. Patients were also evaluated for objective response and toxicity. Results. Of 135 patients registered, 123 were eligible and treated. The subjective symptomatic response rate for 93 symptomatic patients who completed forms was 40%, 95% confidence interval 29-51%. The objective response rate in 77 patients with measurable disease was 19%, 95% confidence interval 11-30%. In patients with both measurable and symptomatic disease, 37% had symptomatic and 13% had objective responses. Median times to treatment failure and death were 4 and 11 months, respectively. Toxicity was greater than anticipated: 12% discontinued treatment due to toxicity, 29% developed at least one Grade 3 neuromuscular toxicity, and two patients died of sepsis while neutropenic. Conclusion. Paclitaxel by 3 hour infusion at a dose of 210 mg/m2 produced excessive neurotoxicity in patients with previously treated metastatic breast cancer. Both sustained subjective symptom reduction and objective responses were demonstrated, but dose reduction for routine practice is recommended.

Original languageEnglish (US)
Pages (from-to)169-181
Number of pages13
JournalBreast Cancer Research and Treatment
Volume51
Issue number2
DOIs
StatePublished - 1998

Fingerprint

Paclitaxel
Breast Neoplasms
Treatment Failure
Confidence Intervals
Therapeutics
Sepsis

Keywords

  • Metastatic breast cancer
  • Paclitaxel
  • Symptom reduction

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Geyer, C. E., Green, S. J., Moinpour, C. M., O'Sullivan, J., Goodwin, D. K., Canfield, V. A., ... Martino, S. (1998). Expanded phase II trial of paclitaxel in metastatic breast cancer: A Southwest Oncology Group study. Breast Cancer Research and Treatment, 51(2), 169-181. https://doi.org/10.1023/A:1006094403153

Expanded phase II trial of paclitaxel in metastatic breast cancer : A Southwest Oncology Group study. / Geyer, Charles E.; Green, Stephanie J.; Moinpour, Carol M.; O'Sullivan, Janet; Goodwin, Donna K.; Canfield, Vikki A.; Meyers, Frederick J.; Osborne, C. Kent; Martino, Silvana.

In: Breast Cancer Research and Treatment, Vol. 51, No. 2, 1998, p. 169-181.

Research output: Contribution to journalArticle

Geyer, CE, Green, SJ, Moinpour, CM, O'Sullivan, J, Goodwin, DK, Canfield, VA, Meyers, FJ, Osborne, CK & Martino, S 1998, 'Expanded phase II trial of paclitaxel in metastatic breast cancer: A Southwest Oncology Group study', Breast Cancer Research and Treatment, vol. 51, no. 2, pp. 169-181. https://doi.org/10.1023/A:1006094403153
Geyer, Charles E. ; Green, Stephanie J. ; Moinpour, Carol M. ; O'Sullivan, Janet ; Goodwin, Donna K. ; Canfield, Vikki A. ; Meyers, Frederick J. ; Osborne, C. Kent ; Martino, Silvana. / Expanded phase II trial of paclitaxel in metastatic breast cancer : A Southwest Oncology Group study. In: Breast Cancer Research and Treatment. 1998 ; Vol. 51, No. 2. pp. 169-181.
@article{34df7df5b8f04ac1bed2c1c4d77cb750,
title = "Expanded phase II trial of paclitaxel in metastatic breast cancer: A Southwest Oncology Group study",
abstract = "Background. The study was designed to evaluate the efficacy of paclitaxel in metastatic breast cancer patients. The design was motivated by a report from FDA and NCI staff proposing assessment of pre- and post-treatment symptoms as a means of evaluating treatment effectiveness. Methods. Patients with symptomatic and/or measurable metastatic breast cancer with prior treatment received paclitaxel 210 mg/m2 as a 3 hour infusion every three weeks until toxicity or progression. A unique endpoint was subjective symptomatic response, defined as an improvement in the Symptom Distress Scale score by ≥ 3 points at two successive evaluations before treatment failure. Patients were also evaluated for objective response and toxicity. Results. Of 135 patients registered, 123 were eligible and treated. The subjective symptomatic response rate for 93 symptomatic patients who completed forms was 40{\%}, 95{\%} confidence interval 29-51{\%}. The objective response rate in 77 patients with measurable disease was 19{\%}, 95{\%} confidence interval 11-30{\%}. In patients with both measurable and symptomatic disease, 37{\%} had symptomatic and 13{\%} had objective responses. Median times to treatment failure and death were 4 and 11 months, respectively. Toxicity was greater than anticipated: 12{\%} discontinued treatment due to toxicity, 29{\%} developed at least one Grade 3 neuromuscular toxicity, and two patients died of sepsis while neutropenic. Conclusion. Paclitaxel by 3 hour infusion at a dose of 210 mg/m2 produced excessive neurotoxicity in patients with previously treated metastatic breast cancer. Both sustained subjective symptom reduction and objective responses were demonstrated, but dose reduction for routine practice is recommended.",
keywords = "Metastatic breast cancer, Paclitaxel, Symptom reduction",
author = "Geyer, {Charles E.} and Green, {Stephanie J.} and Moinpour, {Carol M.} and Janet O'Sullivan and Goodwin, {Donna K.} and Canfield, {Vikki A.} and Meyers, {Frederick J.} and Osborne, {C. Kent} and Silvana Martino",
year = "1998",
doi = "10.1023/A:1006094403153",
language = "English (US)",
volume = "51",
pages = "169--181",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Expanded phase II trial of paclitaxel in metastatic breast cancer

T2 - A Southwest Oncology Group study

AU - Geyer, Charles E.

AU - Green, Stephanie J.

AU - Moinpour, Carol M.

AU - O'Sullivan, Janet

AU - Goodwin, Donna K.

AU - Canfield, Vikki A.

AU - Meyers, Frederick J.

AU - Osborne, C. Kent

AU - Martino, Silvana

PY - 1998

Y1 - 1998

N2 - Background. The study was designed to evaluate the efficacy of paclitaxel in metastatic breast cancer patients. The design was motivated by a report from FDA and NCI staff proposing assessment of pre- and post-treatment symptoms as a means of evaluating treatment effectiveness. Methods. Patients with symptomatic and/or measurable metastatic breast cancer with prior treatment received paclitaxel 210 mg/m2 as a 3 hour infusion every three weeks until toxicity or progression. A unique endpoint was subjective symptomatic response, defined as an improvement in the Symptom Distress Scale score by ≥ 3 points at two successive evaluations before treatment failure. Patients were also evaluated for objective response and toxicity. Results. Of 135 patients registered, 123 were eligible and treated. The subjective symptomatic response rate for 93 symptomatic patients who completed forms was 40%, 95% confidence interval 29-51%. The objective response rate in 77 patients with measurable disease was 19%, 95% confidence interval 11-30%. In patients with both measurable and symptomatic disease, 37% had symptomatic and 13% had objective responses. Median times to treatment failure and death were 4 and 11 months, respectively. Toxicity was greater than anticipated: 12% discontinued treatment due to toxicity, 29% developed at least one Grade 3 neuromuscular toxicity, and two patients died of sepsis while neutropenic. Conclusion. Paclitaxel by 3 hour infusion at a dose of 210 mg/m2 produced excessive neurotoxicity in patients with previously treated metastatic breast cancer. Both sustained subjective symptom reduction and objective responses were demonstrated, but dose reduction for routine practice is recommended.

AB - Background. The study was designed to evaluate the efficacy of paclitaxel in metastatic breast cancer patients. The design was motivated by a report from FDA and NCI staff proposing assessment of pre- and post-treatment symptoms as a means of evaluating treatment effectiveness. Methods. Patients with symptomatic and/or measurable metastatic breast cancer with prior treatment received paclitaxel 210 mg/m2 as a 3 hour infusion every three weeks until toxicity or progression. A unique endpoint was subjective symptomatic response, defined as an improvement in the Symptom Distress Scale score by ≥ 3 points at two successive evaluations before treatment failure. Patients were also evaluated for objective response and toxicity. Results. Of 135 patients registered, 123 were eligible and treated. The subjective symptomatic response rate for 93 symptomatic patients who completed forms was 40%, 95% confidence interval 29-51%. The objective response rate in 77 patients with measurable disease was 19%, 95% confidence interval 11-30%. In patients with both measurable and symptomatic disease, 37% had symptomatic and 13% had objective responses. Median times to treatment failure and death were 4 and 11 months, respectively. Toxicity was greater than anticipated: 12% discontinued treatment due to toxicity, 29% developed at least one Grade 3 neuromuscular toxicity, and two patients died of sepsis while neutropenic. Conclusion. Paclitaxel by 3 hour infusion at a dose of 210 mg/m2 produced excessive neurotoxicity in patients with previously treated metastatic breast cancer. Both sustained subjective symptom reduction and objective responses were demonstrated, but dose reduction for routine practice is recommended.

KW - Metastatic breast cancer

KW - Paclitaxel

KW - Symptom reduction

UR - http://www.scopus.com/inward/record.url?scp=7844225510&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7844225510&partnerID=8YFLogxK

U2 - 10.1023/A:1006094403153

DO - 10.1023/A:1006094403153

M3 - Article

VL - 51

SP - 169

EP - 181

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -